Scarica l'app Stockscreener
125.02
0.14%
-0.18
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GILD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$125.20
Aprire:
$124.81
Volume 24 ore:
6.60M
Relative Volume:
0.96
Capitalizzazione di mercato:
$155.13B
Reddito:
$29.05B
Utile/perdita netta:
$8.11B
Rapporto P/E:
19.36
EPS:
6.4563
Flusso di cassa netto:
$9.16B
1 W Prestazione:
+5.20%
1M Prestazione:
+5.52%
6M Prestazione:
+27.08%
1 anno Prestazione:
+35.73%
Intervallo 1D:
$122.50
$125.64
Intervallo di 1 settimana:
$117.13
$127.68
Portata 52W:
$86.08
$127.68
Gilead Sciences Inc Stock (GILD) Company Profile
Nome
Gilead Sciences Inc
Settore
Industria
Telefono
(650) 574-3000
Indirizzo
333 LAKESIDE DR, FOSTER CITY, CA
Confronta GILD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
125.02 | 155.33B | 29.05B | 8.11B | 9.16B | 6.4563 |
|
LLY
Lilly Eli Co
|
1,025.28 | 915.49B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
195.93 | 470.41B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
232.36 | 410.55B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
131.26 | 253.11B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
92.92 | 230.65B | 63.90B | 19.05B | 13.05B | 7.5596 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-19 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Aggiornamento | Truist | Hold → Buy |
| 2025-07-25 | Aggiornamento | Needham | Hold → Buy |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Reiterato | Oppenheimer | Outperform |
| 2025-02-18 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Aggiornamento | DZ Bank | Hold → Buy |
| 2025-01-10 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Buy |
| 2024-11-08 | Downgrade | Maxim Group | Buy → Hold |
| 2024-10-21 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-10-07 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Reiterato | Maxim Group | Buy |
| 2024-04-24 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Downgrade | Truist | Buy → Hold |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-09-08 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-09-06 | Iniziato | HSBC Securities | Reduce |
| 2023-07-24 | Reiterato | Barclays | Equal Weight |
| 2023-05-16 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Ripresa | Piper Sandler | Overweight |
| 2023-01-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Ripresa | BofA Securities | Neutral |
| 2022-12-09 | Downgrade | DZ Bank | Buy → Hold |
| 2022-10-31 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Reiterato | BMO Capital Markets | Market Perform |
| 2022-10-28 | Reiterato | Cowen | Outperform |
| 2022-10-28 | Reiterato | JP Morgan | Overweight |
| 2022-10-28 | Reiterato | Jefferies | Buy |
| 2022-10-28 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-10-28 | Aggiornamento | Truist | Hold → Buy |
| 2022-10-28 | Reiterato | Wells Fargo | Equal Weight |
| 2022-10-04 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-02-28 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Reiterato | BMO Capital Markets | Outperform |
| 2022-02-02 | Reiterato | BofA Securities | Neutral |
| 2022-02-02 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-02-02 | Reiterato | Truist | Hold |
| 2022-02-02 | Reiterato | Wells Fargo | Equal Weight |
| 2022-01-28 | Aggiornamento | Argus | Hold → Buy |
| 2022-01-06 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-12-06 | Iniziato | Goldman | Neutral |
| 2021-11-19 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Ripresa | Piper Sandler | Neutral |
| 2021-10-20 | Ripresa | Cowen | Outperform |
| 2021-07-30 | Reiterato | BMO Capital Markets | Market Perform |
| 2021-07-30 | Reiterato | RBC Capital Mkts | Outperform |
| 2021-04-01 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Aggiornamento | Redburn | Neutral → Buy |
| 2021-01-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-11-03 | Ripresa | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-09-30 | Ripresa | Jefferies | Buy |
| 2020-09-15 | Aggiornamento | Maxim Group | Hold → Buy |
| 2020-07-31 | Reiterato | Credit Suisse | Neutral |
| 2020-07-31 | Reiterato | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Reiterato | Piper Sandler | Overweight |
| 2020-07-31 | Reiterato | RBC Capital Mkts | Outperform |
| 2020-07-31 | Reiterato | SunTrust | Hold |
| 2020-07-31 | Reiterato | Wells Fargo | Equal Weight |
| 2020-07-20 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Aggiornamento | SunTrust | Sell → Hold |
| 2020-05-01 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Downgrade | SunTrust | Hold → Sell |
| 2020-04-27 | Downgrade | UBS | Buy → Neutral |
| 2020-04-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Downgrade | CFRA | Hold → Sell |
Mostra tutto
Gilead Sciences Inc Borsa (GILD) Ultime notizie
Gilead Sciences, Inc. (GILD)’s Mixed Quarter Draws Divergent Analyst Views - Insider Monkey
Needham & Company LLC Increases Gilead Sciences (NASDAQ:GILD) Price Target to $140.00 - MarketBeat
Daiwa Capital Markets Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price - MarketBeat
Gilead Sciences (NASDAQ:GILD) Coverage Initiated at Scotiabank - MarketBeat
Wealth Alliance LLC Has $1.16 Million Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Bought by Impax Asset Management Group plc - MarketBeat
Police & Firemen s Retirement System of New Jersey Raises Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead scores clinical trial win toward moving HIV patients from multiple-drug regimen to single tablet - The Business Journals
Gilead Sciences, Inc. $GILD Shares Sold by M&G PLC - MarketBeat
Gilead Looks To Simplify HIV Treatment By Combining Two Leading Drugs in One Pill - BioSpace
GILD's Investigational Regimen for HIV Treatment Meets Primary Goal - TradingView
Gilead’s HIV single-pill combo meets primary endpoints in pivotal trial - Yahoo
Is Gilead’s Successful Phase 3 HIV Regimen Trial Shifting the Investment Case for GILD? - Yahoo Finance
Is Gilead Sciences Inc. (GIS) stock inflation resilientTreasury Yields & Risk Managed Investment Strategies - Fundação Cultural do Pará
Credit Capital Investments LLC Makes New Investment in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by Candriam S.C.A. - MarketBeat
Gilead Sciences Insider Sold Shares Worth $6,590,487, According to a Recent SEC Filing - MarketScreener
Gilead Sciences EVP Telman sells $6.59 million in stock By Investing.com - Investing.com Nigeria
Gilead’s Experimental One Pill Regimen Proved Non-Inferior To Multi-Pill Regimens In Treating HIV - Stocktwits
Gilead Sciences EVP Telman sells $6.59 million in stock - Investing.com India
Can Gilead Sciences Inc. stock continue upward trendJuly 2025 Action & Pattern Based Trade Signal System - newser.com
Gilead’s investigational single-tablet regimen of bictegravir and lenacapavir for HIV-1 treatment meets primary endpoint in Phase 3 ARTISTRY-1 trial - European AIDS Treatment Group
Scotiabank Initiates Coverage of Gilead Sciences (GILD) with Sector Outperform Recommendation - Nasdaq
Needham Maintains Gilead Sciences (GILD) Buy Recommendation - Nasdaq
Gilead Sciences (NASDAQ:GILD) Hits New 1-Year HighHere's What Happened - MarketBeat
Will Gilead Sciences Inc. (GIS) stock outperform energy sector in 2025Market Activity Report & Risk Controlled Daily Trade Plans - newser.com
Gilead says single-tablet option matches complex HIV regimens in Phase III study - FirstWord Pharma
GILD's Price Target Raised by Needham to $140.00 | GILD Stock Ne - GuruFocus
Gilead's One-Pill HIV Treatment Shows Promise In Late-Stage TrialGilead Sciences (NASDAQ:GILD) - Benzinga
Gilead stock rises after positive HIV treatment trial results By Investing.com - Investing.com Canada
Gilead stock rises after positive HIV treatment trial results - Investing.com
Gilead Sciences (GILD) Achieves Key Milestone in HIV Treatment T - GuruFocus
Gilead Sciences’ Strategic Advancements in HIV Treatment Bolster Buy Rating and Future Revenue Prospects - TipRanks
Needham Adjusts Gilead Sciences Price Target to $140 From $133, Maintains Buy Rating - MarketScreener
Gilead hits late-stage trial win for new single-tablet HIV therapy - Seeking Alpha
What drives Gilead Sciences Inc GIS stock priceGap Fill Strategies & Stay Safe With Built-In Risk Monitoring - earlytimes.in
What drives Gilead Sciences Inc. stock priceGlobal Market Influence & Free Tap Rapid Wealth - earlytimes.in
Gilead hails phase 3 victory for single-tablet combo of bictegravir and lenacapavir, preps filings - Fierce Pharma
Gilead (GILD) Reveals Promising Phase 3 Trial Results for HIV Tr - GuruFocus
Gilead Reports Positive Phase 3 Results For Bictegravir/ Lenacapavir Single-tablet Regimen For HIV - Nasdaq
Gilead reports positive results for HIV single-tablet regimen By Investing.com - Investing.com Australia
Daiwa Securities Adjusts Gilead Sciences Price Target to $129 From $128, Maintains Outperform Rating - MarketScreener
This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Can Gilead Stock Outrun Regeneron In The Next Rally? - Forbes
Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial - Yahoo Finance
Geode Capital Management LLC Buys 727,515 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
United Asset Strategies Inc. Sells 2,099 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by Mitsubishi UFJ Trust & Banking Corp - MarketBeat
KBC Group NV Raises Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead price attacks pivotal resistanceForecast today13-11-2025 - Economies.com
National Pension Service Sells 211,960 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences Inc Azioni (GILD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Gilead Sciences Inc Azioni (GILD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Telman Deborah H | EVP, Corporate Affairs & GC |
Nov 12 '25 |
Sale |
122.85 |
53,646 |
6,590,487 |
43,676 |
1.83%
0.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):